PATHOGENETIC ROLE OF A sFas APOPTOSIS INHIBITOR

Download full text PDF
Issue: 
5
Year: 
2015

M. Ploskonos (1,2), Candidate of Biological Sciences; Professor A. Nikolaev, MD 1 -Astrakhan State Medical University 2 -Volga State University of Water Transport; Caspian Institute of Sea and River Transport, Branch, Volga State University of Water Transport, Astrakhan

The change in the blood concentration of sFas antigen, the function of which is aimed at maintaining systemic homeostasis, reflects the activity of pathological processes occurring in the body. The findings may suggest that the serum level of sFas antigen is of obvious prognostic and monitoring value.
Keywords: 
sFas
blood
apoptosis

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Abbasova S.G. Rastvorimyj Fas pri onkologicheskih zabolevanijah. Avtoref. dis. … d-ra biol. nauk. M., 2008; 51 s.
  2. Baryshnikov A.Ju., Shishkin Ju.V. Immunologicheskie problemy apoptoza / M.: Editorial URSS, 2002; 320 s.
  3. Belushkina N.N., Severin S.E. Molekuljarnye osnovy patologii apoptoza // Arh. patol. – 2001; 1: 51–60.
  4. Britvin T.A. Rastvorimyj Fas-antigen (sFas) pri rake kory nadpochechnika // Klin. lab. diagn. – 2005; 9: 19.
  5. Bulgakova V.A. Klinicheskoe znachenie izuchenija markerov aktivatsii i apoptoza immunokompetentnyh kletok pri atopicheskoj bronhial'noj astme u detej // Pediatrija. – 2009; 87 (2): 12–8.
  6. Evsegneeva I.V., Manakova E.A., Novikov V.V. i dr. Povyshennyj uroven' rastvorimyh antigenov CD50, CD95 i HLA I klassa v syvorotke krovi bol'nyh gepatitom A // Tsitokiny i vospalenie. – 2005; 4 (3): 25–7.
  7. Nadzhafipur R., Dolgov V.V., Orlova O.V. i dr. Markery Fas- oposredovannogo apoptoza u bol'nyh s serdechnoj nedostatochnost'ju // Klin. lab. diagn. – 2007; 10: 19–37.
  8. Nedosekova Ju.V., Urazova O.I., Kravets E.B. i dr. Rol' apoptoza v razvitii autoimmunnyh zabolevanij schitovidnoj zhelezy // Bjul. sibirskoj meditsiny. – 2009; 1: 64–71.
  9. Neljubin E.V. Immunologicheskie narushenija i apoptoticheskaja reaktivnost' limfotsitov perifericheskoj krovi pri psoriaze. Avtoref. dis. … kand. med. nauk. Ekaterinburg, 2007; 35 s.
  10. Nikolaev A.A., Ploskonos M.V. Immunofermentnyj analiz Fas-retseptora (SD 95) u lits s patologiej predstatel'noj zhelezy // Sovrem. naukoemkie tehnol. – 2008; 3: 89–90.
  11. Nikolaev A.A., Ploskonos M.V. Sposob prognozirovanija stepeni zlokachestvennosti raka predstatel'noj zhelezy. Patent na izobretenie №2521229 ot 29 aprelja 2014 g.
  12. Novikov V.V., Baryshnikov A.Ju., Karaulov A.V. Rastvorimye formy membrannyh antigenov kletok immunnoj sistemy // Immunologija. – 2007; 4: 249–53.
  13. Obusheva M.N., Abbasova S.G., Ljakina L.T. i dr. Rastvorimyj Fas-antigen u bol'-nyh epitelial'nymi opuholjami jaichnikov // Klin. lab. diagn. – 2005; 9: 18.
  14. Orlova O.V., Nadzhafipur R., Shevchenko O.P. i dr. Rastvorimye formy markerov Fas-oposredovannogo apoptoza pri serdechnoj nedostatoch-nosti // Klin. lab. diagn. – 2006; 9: 38.
  15. Ploskonos M.V., Nikolaev A.A. Rastvorimaja forma markera Fas-oposredovannogo apoptoza u patsientov s idiopaticheskim besplodiem // Allergol. i immunol. – 2008; 3: 310.
  16. Ploskonos M.V., Nikolaev A.A. Diagnosticheskoe znachenie urovnja rastvorimogo Fas-antigena pri zabolevanijah predstatel'noj zhelezy // Klin. lab. diagn. – 2008; 9: 82.
  17. Ploskonos M.V., Nikolaev A.A. Rastvorimyj Fas-antigen (sFas) u bol'nyh rakom predstatel'noj zhelezy. Mat-ly IV (XIII) Mezhd. nauch. konf. «Oncology – HHI Century. Public Health and Education». Hoshimin: Izd-vo «Knizhnyj format», 2009; s. 208.
  18. Ploskonos M.V., Nikolaev A.A. Rastvorimaja forma membrannogo Fas-antigena (sFas-antigena) v norme i pri patologii // Astrahanskij med. zhurn. – 2010; 4: 20–7.
  19. Samuilov V.D., Aleksin A.V., Lagunova E.M. Programmirovannaja kletochnaja gibel' // Biohimija. – 2000; 65 (8): 1029–46.
  20. Shevchenko O.P., Orlova O.V., Kozlova O.D. i dr. Dinamika markerov apoptoza (sFas/sFasL) pri lechenii patsientov s zastojnoj serdechnoj nedo-statochnost'ju // Klin. lab. diagn. – 2005; 10: 49.
  21. Jarilin A.A., Nikonova M.F., Jarilina A.A. i dr. Apoptoz, ego rol' v patologii, znachimost' ego otsenki pri kliniko-immunologicheskom obsledo-vanii bol'nyh // Med. immunol. – 2000; 2: 7–16.
  22. Cascino I., Fiucci G., Papoff G. et al. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing // J. Immunol. – 1995; 154 (6): 2706–13.
  23. Cheng J., Zhou T., Liu C. et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule // Science. – 1994; 263 (5154): 1759–62.
  24. Furuya Y., Nagakawa O., Fuse H. Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer // Endocr. J. – 2003; 5: 629–33.
  25. Knipping E., Debatin K., Stricker K. et. al. Identification of soluble APO-1 in super-natants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias // Blood. – 1995; 85 (6): 1562–9.
  26. Smolewska E., Brozik H., Smolewski P. et al. Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis // Ann. Rheum. Diseas. – 2003; 62: 761–3.
  27. Songye X., Xing D., Jiting C. et al. Clinical significance of serum levels of soluble Fas, soluble Fas ligand and soluble TNFR-II in patients with chronic congestive heart failure. 2004; Abs. №1680–6115.
  28. Vermes I., Haanen C., Reutelingsperger C. Flow cytometry of apoptotic cell death // J. Immunol. Methods. – 2000; 243: 167–90.
  29. Weetman A., McGregor A. Antigen presentation in the pathogenesis of 29. autoimmune endocrine disease // J. Autoimmun. – 1995; 3: 305–12.